Moderna, Merck mRNA cancer vaccine prevents melanoma from returning

An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.   The positive results mean a potentially life-extending treatment is one step closer to being available on the market. They also herald a significant and…